Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

OrbiMed Raises $551 Million for Third Asia Healthcare Fund

publication date: Sep 5, 2017

OrbiMed, a global healthcare investor, closed its third Asia private equity fund with $551 million in capital commitments, about $100 million more than the target listed in its initial filing six months ago. OrbiMed Asia Partners III will consider investments in all parts of Asia healthcare, but it expects to focus on growth-stage product and service companies in China and India. The Fund plans to make 15-20 investments that range from $10 to $75 million each. OrbiMed's two previous Asia funds totaled slightly less than $500 million. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020